Overview
- The companies announced a multi-program research collaboration to create enzymes for genetic medicine that act at exact DNA addresses.
- Profluent will receive an upfront payment and research funding and could earn up to $2.25 billion in milestone payments plus tiered royalties on sales.
- Profluent plans to use generative AI to build designer recombinases, which are proteins meant to place or swap kilobase-scale DNA at chosen genome sites.
- Lilly will hold an exclusive license to move selected enzymes into animal studies, then into preclinical work, clinical trials, and possible commercialization.
- No disease targets, timelines, or preclinical results were disclosed, signaling an early research effort with significant technical and regulatory hurdles still ahead.